Adolore BioTherapeutics is developing non-opioid gene therapies for chronic pain and neurological disorders. Founded by Roy Clifford Levitt with scientific cofounder Joseph C. Glorioso, the company’s approach uses CA8-related technology and gene-delivery vectors to modulate nerve signaling. [1] [2]
Its development programs include erythromelalgia and chronic osteoarthritis knee pain. The platform draws on technology licensed from the University of Miami and the University of Pittsburgh. Adolore’s erythromelalgia program received FDA Orphan Drug Designation in January 2026, while NIH/NINDS HEAL support is helping advance its knee-pain research toward first-in-human testing. [3] [4] [5]